Tags

Type your tag names separated by a space and hit enter

Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Lab Hematol. 2006; 12(4):187-92.LH

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and proapoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P<.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P<.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P<.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P<.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.

Authors+Show Affiliations

Department of Clinical Pathology, AO Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17118768

Citation

Scamardella, F, et al. "Abnormal Intracellular Level of Bax in CD3+ Cells From Untreated B-cell Chronic Lymphocytic Leukemia Patients." Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology, vol. 12, no. 4, 2006, pp. 187-92.
Scamardella F, Maconi M, Albertazzi L, et al. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. Lab Hematol. 2006;12(4):187-92.
Scamardella, F., Maconi, M., Albertazzi, L., Gamberi, B., Gugliotta, L., & Brini, M. (2006). Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology, 12(4), 187-92.
Scamardella F, et al. Abnormal Intracellular Level of Bax in CD3+ Cells From Untreated B-cell Chronic Lymphocytic Leukemia Patients. Lab Hematol. 2006;12(4):187-92. PubMed PMID: 17118768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. AU - Scamardella,F, AU - Maconi,M, AU - Albertazzi,L, AU - Gamberi,B, AU - Gugliotta,L, AU - Brini,M, PY - 2006/11/23/pubmed PY - 2007/2/16/medline PY - 2006/11/23/entrez SP - 187 EP - 92 JF - Laboratory hematology : official publication of the International Society for Laboratory Hematology JO - Lab Hematol VL - 12 IS - 4 N2 - B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and proapoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P<.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P<.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P<.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P<.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis. SN - 1080-2924 UR - https://www.unboundmedicine.com/medline/citation/17118768/Abnormal_intracellular_level_of_Bax_in_CD3+_cells_from_untreated_B_cell_chronic_lymphocytic_leukemia_patients_ L2 - http://www.diseaseinfosearch.org/result/4193 DB - PRIME DP - Unbound Medicine ER -